Reversible Restrictive Lung Disease in Pseudomesotheliomatous Carcinoma in a Lung Harboring a HER2-mutation

Pseudomesotheliomatous carcinoma of the lung is very rare, and reversible restrictive lung disease with pseudomesotheliomatous carcinoma has not yet been previously reported. We herein report a patient with HER2-positive non-small-cell lung cancer (NSCLC) showing pseudomesotheliomatous carcinoma who...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2018/08/01, Vol.57(15), pp.2223-2226
Main Authors: Sakata, Shinya, Sakamoto, Yasumiko, Takaki, Akira, Ishizuka, Shiho, Saeki, Sho, Fujii, Kazuhiko
Format: Article
Language:English
Subjects:
Bevacizumab
Case Report
Chemotherapy
Cisplatin
Dyspnea
ErbB-2 protein
HER2
Internal medicine
Lung cancer
Lung carcinoma
Lung diseases
Monoclonal antibodies
Non-small cell lung carcinoma
pseudomesotheliomatous carcinoma
Pulmonary functions
Respiration
Respiratory function
restrictive lung disease
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pseudomesotheliomatous carcinoma of the lung is very rare, and reversible restrictive lung disease with pseudomesotheliomatous carcinoma has not yet been previously reported. We herein report a patient with HER2-positive non-small-cell lung cancer (NSCLC) showing pseudomesotheliomatous carcinoma who was successfully treated with bevacizumab combination chemotherapy. A 56-year-old Japanese woman with advanced NSCLC presented with dyspnea. We administered chemotherapy with cisplatin (75 mg/m2) plus pemetrexed (500 mg/m2) plus bevacizumab (15 mg/kg), followed by pemetrexed plus bevacizumab. After eight cycles of maintenance chemotherapy, chest CT demonstrated a marked tumor reduction and an improvement of the right lung volume. The vital capacity was thereafter found to have significantly increased according to pulmonary function tests.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.9612-17